


Patent claims:

1. A compound according to Formula I or a physiologically well tolerated salt thereof



5        wherein X and Y may be identical or different, and may be -Hal, -H, -O-R<sub>10</sub>, -NH<sub>2</sub>, - (CR<sub>20</sub>R<sub>20</sub>)<sub>n</sub>-O-NH<sub>2</sub>, C<sub>n</sub> alkyl (saturated, single or multiple unsaturated), C<sub>n</sub> aryl, -NO<sub>2</sub>,

10        wherein R<sub>10</sub> may be -H, C<sub>n</sub> alkyl (saturated, single or multiple unsaturated), C<sub>n</sub> aryl,

15        wherein R<sub>1</sub> may be -H, C<sub>n</sub> alkyl (saturated, single or multiple unsaturated), C<sub>n</sub> aryl, -CH(ONXY)<sub>2</sub>, -C(ONXY)<sub>3</sub>, -(CR<sub>20</sub>R<sub>20</sub>)<sub>n</sub>-(CO)<sub>x</sub>-(CR<sub>20</sub>R<sub>20</sub>)<sub>n</sub>-(O)<sub>x</sub>-R<sub>20</sub>, -(CR<sub>20</sub>R<sub>20</sub>)<sub>n</sub>-CR<sub>110</sub>-R<sub>111</sub>, -(CR<sub>20</sub>R<sub>20</sub>)<sub>n</sub>-NXY, -SO<sub>2</sub>-R<sub>20</sub>, -O-R<sub>20</sub>, -(CR<sub>20</sub>R<sub>20</sub>)<sub>n</sub>-(O)<sub>x</sub>-(CO)<sub>x</sub>-R<sub>110</sub>,

      wherein R<sub>110</sub> may be =O, -Hal, -COOH, -CN, -SCN, -CNS, -CNO, -N=N-H, -O-CN, -(CO)-CN, -N=N,

      wherein R<sub>111</sub> may be identical to R<sub>10</sub>, -O-R<sub>10</sub>,

20        wherein R<sub>20</sub> may be respectively independently -H, -OH, -Hal, C<sub>n</sub> alkyl (saturated, single or multiple unsaturated), C<sub>n</sub> aryl, -AS, -NXY, -Z, -C(NH<sub>2</sub>)-COOH, -(CO) -CN, -COOH, R<sub>110</sub>, benzyl (unsubstituted or -Hal and/or -OH and/or -ONXY and/or C<sub>n</sub> alkoxy substituted), -PO<sub>3</sub><sup>2-</sup>, -P<sub>2</sub>O<sub>5</sub><sup>3-</sup>,

25        wherein -O- may be replaced respectively independently by -S- or -Se-,

      wherein n may be respectively independently every integer number from 0 to 18,

wherein r is respectively independently 0 or 1,

5 wherein AS represents respectively independently an amino acid residue, which is obtained by removal of the amino group of an amino acid, or the residue of an amino acid, which is bound to the  $\alpha$ -C of an amino acid, or  $\text{COOH-CH-NH}_2$ ,

wherein -Hal is -F, -Cl, -Br, or -J,

10 wherein -Z is a residue according to one of the following Formulas II to V,

wherein -COOH may be replaced respectively independently by  $-\text{COOR}_{10}$ , -CHO, -CN,  $-(\text{CO})-\text{NXY}$ ,  $-\text{C}(\text{NXY})_2$ ,  $-\text{CH-O-NXY}$ ,  $-\text{C}(\text{OH})-\text{O-NXY}$ ,  $-(\text{CO})-\text{O-NXY}$ ,  $-(\text{CO})-\text{CN}$ ,

15 wherein free valences are bound by -H,


wherein XYN- or XYN-O- in Formula I may be replaced by NC-, NCS-, NCO-, SNC-, ONC-,  $\text{HN=N-}$ ,  $\text{N=N-}$ .

20




25

30

35



Formula II



2. The use of a compound according to claim 1 for the production of a pharmaceutical composition for treating one or several different diseases from the group consisting of "cancer, rheumatism, (chronic) inflammations, asthma, arthritis, osteoarthritis, chronic polyarthritis, rheumatic arthritis, inflammatory bowel disease, degenerative joint diseases, diseases of the rheumatic type with cartilage degradation, sepsis, autoimmune diseases, type I diabetes, Hashimoto's thyroiditis, autoimmune thrombocytopenia, multiple sclerosis, myasthenia gravis, chronically inflammatory bowel diseases, Crohn's disease, uveitis, psoriasis, connective tissue diseases, Goodpasture's syndrome, diseases with disturbed adhesion of leukocytes, cachexia, diseases by increased TNFalpha concentration, diabetes, adiposity, bacterial infections, in particular with resistant bacteria (antibiotic), heart insufficiency, chronic cardiac failure (CCF), acidosis".

3. A pharmaceutical composition, wherein a compound according to claim 1 is mixed with one or several physiologically well tolerated auxiliary and/or carrier substances, and is galenically prepared for the local, in particular oral or systemic, in particular IV administration.

4. The use of a compound according to the claim 1 for the in vitro and/or in vivo inhibition of the glycolysis and/or of the glutaminolysis, in particular of pyruvate kinase, asparaginase, serine dehydratases, transaminases, glutamate-oxalacetate transaminase, glutamate-pyruvate transaminase, glutamate-dehydrogenase,

malate dehydrogenase, desaminases, and/or glutaminases, in particular in prokaryotes and/or eukaryotes.